BRAF and melanoma: Also, the hyperactivation of MAPK signaling increases reactive oxygen species (ROS) levels in BRAF inhibitor-resistant melanoma cells [34], and histone deacetylase inhibitor vorinostat boosts ROS levels, selectively killing drug-resistant tumor cells [47].